<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872777</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00017544</org_study_id>
    <nct_id>NCT04872777</nct_id>
  </id_info>
  <brief_title>Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH</brief_title>
  <official_title>Mobile Health Delivered Lifestyle Intervention Program in Patients With Nonalcoholic Steatohepatitis: A Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Noom Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a clear unmet clinical need for effective lifestyle intervention in patients with&#xD;
      nonalcoholic steatohepatitis (NASH). Patients have self-identified multiple barriers to&#xD;
      effective lifestyle intervention can be removed with a mobile health (mHealth) platform.&#xD;
&#xD;
      This study will be a proof of concept study to evaluate weight loss efficacy of Noom Healthy&#xD;
      Weight (HW), a mHealth lifestyle intervention, in patients with NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Forty-subjects with NASH will be randomized 1:1 to either receive Noom HW mHealth lifestyle intervention or standard clinical care.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in self-measured body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver enzymes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in liver enzymes units per liter (alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noom healthy weight engagement</measure>
    <time_frame>16 weeks</time_frame>
    <description>Feasibility will be assessed according to user engagement. Engaged users are defined as those who complete at least one meaningful in-application action per week (e.g., weight log, food log, exercise log, article read).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in blood glucose mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin A1c</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change hemoglobin A1c (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol level</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in cholesterol mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAFLD Fibrosis Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>change in NAFLD Fibrosis Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA level</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in IgA level mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in Ferritin ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histology</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in transient elastography or liver histology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care (SOC) control condition: Following study group assignment, the following procedures will be completed for SOC control:&#xD;
Digital scale provision (subjects may keep the scale)&#xD;
Reinforcement of need to comply with SOC treatment as directed by their NASH clinician&#xD;
Capture of available clinical information over preceding 28-days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Noom Healthy Weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:&#xD;
Noom application set-up and troubleshooting on smartphone (license provided)&#xD;
Digital scale provision (subjects may keep the scale)&#xD;
Capture of available clinical information over preceding 28-days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Noom Healthy Weight</intervention_name>
    <description>Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:&#xD;
Noom application set-up and troubleshooting on smartphone (license provided)&#xD;
Digital scale provision (subjects may keep the scale)&#xD;
Capture of available clinical information over preceding 28-days.</description>
    <arm_group_label>Noom Healthy Weight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age &gt;18 years&#xD;
&#xD;
          -  NASH defined as:&#xD;
&#xD;
          -  Liver biopsy with evidence of steatohepatitis (NAS &gt;=4) or;&#xD;
&#xD;
          -  Imaging study (e.g., ultrasound, CT, MRI) with hepatic steatosis and one of the&#xD;
             following:&#xD;
&#xD;
          -  Fibroscan kPa &gt;8.2 or;&#xD;
&#xD;
          -  FAST &gt; 0.35 or;&#xD;
&#xD;
          -  FIB-4 &gt;= 1.45 or;&#xD;
&#xD;
          -  Possession of a smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or recent (&lt;90 days) participation in lifestyle intervention program, including&#xD;
             weight-loss program&#xD;
&#xD;
          -  Active weight-loss supplement use&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Institutionalized/prisoner&#xD;
&#xD;
          -  Other chronic liver disease (e.g., viral hepatitis)&#xD;
&#xD;
          -  Recent Noom use (&lt;180 days)&#xD;
&#xD;
          -  Secondary cause of hepatic steatosis, including significant alcohol consumption (men&#xD;
             &gt;30g/d, women &gt;20g/d)&#xD;
&#xD;
          -  Severe medical comorbidities/psychiatric illness at the discretion of the study PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan G Stine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloriany Rivas, BA</last_name>
    <phone>7175310003</phone>
    <phone_ext>320223</phone_ext>
    <email>grivas@pennstatehealth.psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Marietta</city>
        <state>Pennsylvania</state>
        <zip>17547</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloriany Rivas, BA</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>320223</phone_ext>
      <email>grivas@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Stine</investigator_full_name>
    <investigator_title>Director of Research, Penn State Liver Center, Assistant Professor of Medicine and Public Health Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

